Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.42 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PDE1A | P54750 | 1/20 | 0.39 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | GPR18 | Q14330 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5405558 | 0.90 | SLC16A1 (0.47) | SLC16A1TP53MAPTCYP2C9PDE1A | |
| SCHEMBL5398894 | 0.88 | SLC16A1 (0.49) | SLC16A1TP53MAPTCYP2C9MAPKAPK2 | |
| SCHEMBL5399735 | 0.88 | SLC16A1 (0.51) | SLC16A1TP53MAPTCYP2C9MAPKAPK2 | |
| SCHEMBL5400640 | 0.88 | SLC16A1 (0.54) | SLC16A1TP53MAPTCYP2C9MAPKAPK2 | |
| SCHEMBL5400652 | 0.87 | MAPT (0.48) | SLC16A1TP53MAPTPDE1APDE1B | |
| SCHEMBL5407653 | 0.87 | TP53 (0.40) | TP53MAPTMEN1KMT2APDE1A | |
| SCHEMBL5405716 | 0.87 | TP53 (0.44) | SLC16A1TP53MAPTPDE1APDE1B | |
| SCHEMBL5405616 | 0.87 | SLC16A1 (0.51) | SLC16A1TP53MAPTCYP2C9MAPKAPK2 | |
| SCHEMBL5404242 | 0.86 | XIAP (0.46) | SLC16A1TP53MAPTCYP2C9PDE5A | |
| SCHEMBL6659477 | 0.86 | TP53 (0.41) | TP53MAPTPDE5APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1573000-B1 | CRYSTAL STRUCTURE OF GLUTAMATE RACEMASE (MURI) | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
| EP-1412355-A1 | NEW PYRAZOLO(3,4-D)PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | AstraZeneca AB (SE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003002567-A1 | NEW PYRAZOLO[3,4-D]PYRIMIDINES INHIBITING H. PYLORI INFECTIONS | ASTRAZENECA AB (SE) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | SLC16A1 4140/4885TP53 1580/4885MAPT 4180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.